Insider buying last 90 days
No open-market insider purchases were filed for REPL in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every REPL insider filing, plotted on the chart in Gekko.Open REPL in Gekko
NASDAQ: REPL
Replimune (REPL) Stock Analysis & Forecast
Oct 12 close
$13.07−0.35 (−2.6%)
Gekko Brief
AI summaryOct 12 closeReplimune's week centers on the accelerated FDA approval of its first commercial drug, Tudriqev, for advanced cutaneous melanoma, alongside reporting that current capital is expected to last only until Q1 2027, ahead of confirmatory trial data due in 2030. Cantor Fitzgerald reiterated an Overweight rating following the launch, even as commentary flagged rapid cash burn tied to the rollout. Separately, securities class action filings from Bronstein, Gewirtz & Grossman and Levi & Korsinsky allege securities law violations tied to prior disclosures around the RP1 resubmission and the FDA's earlier rejection letter.
Shares close at $13.07, down 2.6%, sitting between the 50-day average of $13.82 and the 200-day average of $9.03. The GekkoIndex reads 59.8, placing REPL in the Neutral zone. Fair value stands at $14.82, putting price 11.8% below that mark. One-year return sits at 186%, with the stock off its 52-week high of $16.33 and well above its 52-week low of $1.50.
Earnings are set for 5 November 2026, 23 days out and inside a typical 20-trading-day holding window; the last report showed a loss of $0.72 per share against a $0.69 estimate, with a -3.7% reaction. No insider, Congress or unusual options activity appears in the respective 90-day and 30-day windows. Seasonality from this point has averaged a 15% gain over the next 20 trading days across 5 years, rising in 4 of them. Consensus among 8 analysts remains all-buy, with a $19.50 price target.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Replimune price vs fair value
Close $13.07200-day averageGekko Fair Value $14.82
Replimune quick facts
- Market cap
- $1.10B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$3.24
- Revenue, TTM
- $0
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 0.94
- Volume
- 1.16M avg 2.05M
- 1-year return
- +186.0%
- Typical daily move
- ±5.7%
- Typical 20-day move
- ±14.1%
- 50-day average
- $13.82
- 200-day average
- $9.03
- Next earnings
- Nov 5
- Shares outstanding
- 94.22M
Replimune swing-trade checklist
Replimune scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
- Trendmixed
Averages disagree
Close $13.07 sits between the 50-day ($13.82) and 200-day ($9.03) averages, or the averages disagree.
See the chart - GekkoIndexmixed
59.8, Neutral
Reading 59.8 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
11.8% below
Price is 11.8% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 24 days
Reports on Nov 5, 2026, 24 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+15.0% on average
From this point in the calendar, the next 20 trading days averaged +15% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Replimune stock chart and price history
Replimune closed at $13.07 on Oct 12, 2026, +186.0% over the past year, inside a 52-week range of $1.50 to $16.33.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +1.2%
- 3 months
- +31.5%
- 6 months
- +174.6%
- 1 year
- +186.0%
The full REPL chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open REPL in Gekko
Follow Replimune through every session
Put REPL on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track REPL in GekkoFree for 7 days. No credit card required.
About Replimune
Replimune works in biotechnology, developing gene-based therapies that use modified viruses to help the immune system attack cancer cells. Its platform is used to build these therapies, with RP1, a modified form of the herpes simplex virus, as its most advanced candidate. RP1 is being tested in early and mid-stage trials across several solid tumor types, including a Phase II study focused on cutaneous squamous cell carcinoma.
Beyond RP1, the company is advancing two additional candidates. RP2 is a protein designed to block CTLA-4, a molecule that can dampen immune responses, and is currently in Phase I testing. RP3 is also in Phase I trials and is built to prompt the expression of proteins that activate T cells, a type of immune cell involved in fighting disease. Each program centers on turning the immune system against tumors rather than targeting cancer cells directly with conventional drugs.
Replimune was founded in 2015 and is headquartered in Woburn, Massachusetts. Its shares are listed on the NASDAQ under the ticker REPL.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- replimune.com
Replimune GekkoIndex: the smart money zone
Replimune’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 59.8, in the Neutral zone, up 0.7 points over five sessions.
59.8Neutral
Up 0.7 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 54 | Not available | |||
| Accumulation | 214 | +3.5% | +12.6% | ||
| Neutral (current zone) | 388 | +1.1% | +2.4% | ||
| Distribution | 23 | −15.0% | −9.9% | ||
| Selling | 2 | Too few readings yet | |||
Average REPL share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the REPL price, zone by zone.Track REPL in Gekko
Is Replimune stock overvalued? Gekko Fair Value
Replimune trades 11.8% below Gekko Fair Value of $14.82, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Replimune shares are worth, recalculated every trading day.
$14.82
Gekko Fair Value, Oct 10, 2026
11.8% Undervalued
At the end of Aug 2026 the price was 9.4% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open REPL in Gekko
Replimune insider and Congress trading
No open-market insider purchases were filed for Replimune, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in REPL were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for REPL, plotted on the chart in Gekko.Open REPL in Gekko
Hedge funds and billionaires quarter ended Jun 30
0of the funds Gekko tracks hold REPL.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Replimune earnings: next date and track record
Replimune reports on Nov 5, 2026 (24 days away), and beat the EPS estimate in 2 of its last 8 reports.
Next earnings report
Nov 5, 2026
24 days away
- EPS estimate
- −$0.78
- Revenue estimate
- $1.00M
2 of 8reports beat the EPS estimate
±4.3%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 14, 2026 | −$0.72 est −$0.69 | — est $13.60M | −3.7% |
| Feb 3, 2026 | −$0.77 est −$0.77 | — est $429K | +0.3% |
| Nov 6, 2025 | −$0.90 est −$0.87 | — est $714K | −3.1% |
| Aug 7, 2025 | −$0.95 est −$0.83 | — est $500K | −3.8% |
| May 22, 2025 | −$0.82 est −$0.75 | $1.47M | −1.3% |
| Feb 12, 2025 | −$0.79 est −$0.70 | — | +11.2% |
| Nov 12, 2024 | −$0.68 est −$0.74 | — | −6.5% |
| Aug 8, 2024 | −$0.78 est −$0.85 | — | +4.1% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Replimune stock forecast and analyst price targets
Analysts’ average 12-month price target for Replimune is $19.50, +49.2% from the last close, from 8 firms rating the stock in the last 90 days.
$19.50consensus 12-month target, +49.2% from the last close
Now $13.07Avg $19.50
Low $14High $24
Each firm’s latest rating in the last 90 days: 8 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 10 | Kempen & Co | $19 | +45.4% |
| Aug 26 | J.P. Morgan | $21 | +60.7% |
| Aug 17 | Jefferies | $24 | +83.6% |
| Aug 17 | Wedbush | $19 | +45.4% |
| Aug 17 | BMO Capital | $20 | +53.0% |
+2.4%average 20-day move after past Neutral readings
+15.0%average move over the next 20 trading days in the last 5 years
±5.7%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Replimune seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Replimune averaged +15.0% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.2% | 1 of 5 |
| Next 10 trading days | +17.8% | 3 of 5 |
| Next 15 trading days | +24.4% | 4 of 5 |
| Next 20 trading days | +15.0% | 4 of 5 |
| Next 30 trading days | +17.6% | 3 of 5 |
For scale, REPL’s typical 20-trading-day move in either direction is about 14.1%.
Replimune market cap and key statistics
Replimune’s market cap is $1.10B and revenue of $0 over the last twelve months.
Valuation
- Market cap
- $1.10B
- EPS, TTM
- −$3.24
- Gekko Fair Value
- $14.82
Trading
- Volume
- 1.16M
- Avg volume, 20 days
- 2.05M
- 52-week high
- $16.33
- 52-week low
- $1.50
- Shares outstanding
- 94.22M
Financials
- Revenue, TTM
- $0
- Profit margin
- 0%
- Return on equity
- -134.3%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.94
- Typical daily move
- ±5.7%
- Typical 20-day move
- ±14.1%
Replimune stock news this week
Coverage of Replimune this week reads neutral: 2 positive, 3 neutral and 2 negative headlines.
- Replimune’s First Commercial Drug Arrives—With A 2027 Cash Cliff And 2030 Finish LineStocktwits, Oct 8
- (REPL) Movement as an Input in Quant Signal SetsStock Traders Daily, Oct 7
- Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire, Oct 6
- Cantor Fitzgerald reiterates Overweight on Replimune Group stockInvesting.com, Oct 5
- Cantor Fitzgerald reiterates Overweight on Replimune Group stock By Investing.comInvesting.com UK, Oct 5
- Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPLGlobeNewsWire, Oct 5
Replimune peers
Replimune’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
Replimune stock FAQ
What is Replimune’s market cap?
Replimune’s market cap is $1.10B at the Oct 12, 2026 close of $13.07, with 94.22M shares outstanding.
What is the Replimune stock forecast?
The consensus analyst 12-month price target for Replimune is $19.50, +49.2% from the last close. Of the 8 firms that rated the stock in the last 90 days, 8 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Replimune stock overvalued or undervalued?
On Gekko’s estimate Replimune is undervalued: the Oct 12, 2026 close of $13.07 is 11.8% below Gekko Fair Value of $14.82. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Replimune report earnings next?
Replimune is expected to report on Nov 5, 2026 (24 days away). Analysts expect earnings of −$0.78 per share on revenue of $1.00M. Replimune beat the earnings estimate in 2 of its last 8 reports, moving 4.3% on average across the report.
What is Replimune’s 52-week high and low?
Replimune’s 52-week high is $16.33 and its 52-week low is $1.50; it closed at $13.07 on Oct 12, 2026, +186.0% over the past year. Over the last five years the shares peaked at $35.93 on Nov 19, 2021.
Is Replimune stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (fair value and seasonality), 2 as mixed (trend and gekkoindex) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Replimune the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.